



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

JA

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
08/945,731	11/10/97	CROS	P WPB-40330

HM12/0408

EXAMINER	
----------	--

OLIFF & BERRIDGE  
PO BOX 19928  
ALEXANDRIA VA 22320

SANDALS, W

ART UNIT	PAPER NUMBER
----------	--------------

1636

8

DATE MAILED: 04/08/99

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

## Office Action Summary

Application No. 08/945,731	Applicant(s) os, Elaissari, Mabilat, Pichot, Rodrigue And Santo
Examiner WILLIAM SANDALS	Group Art Unit 1636

Responsive to communication(s) filed on Feb 1, 1999

This action is **FINAL**.

Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

### Disposition of Claims

Claim(s) 1-22 is/are pending in the application.

Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

Claim(s) \_\_\_\_\_ is/are allowed.

Claim(s) 1-22 is/are rejected.

Claim(s) \_\_\_\_\_ is/are objected to.

Claims \_\_\_\_\_ are subject to restriction or election requirement.

### Application Papers

See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.

The proposed drawing correction, filed on \_\_\_\_\_ is  approved  disapproved.

The specification is objected to by the Examiner.

The oath or declaration is objected to by the Examiner.

### Priority under 35 U.S.C. § 119

Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

All  Some\*  None of the CERTIFIED copies of the priority documents have been

received.

received in Application No. (Series Code/Serial Number) \_\_\_\_\_.

received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_.

Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

### Attachment(s)

Notice of References Cited, PTO-892

Information Disclosure Statement(s), PTO-1449, Paper No(s). \_\_\_\_\_

Interview Summary, PTO-413

Notice of Draftsperson's Patent Drawing Review, PTO-948

Notice of Informal Patent Application, PTO-152

... SEE OFFICE ACTION ON THE FOLLOWING PAGES ...

Feb 5  
Att H J

Art Unit: 1636

## **DETAILED ACTION**

### ***Response to Arguments***

1. Applicant's amendments to the specification in Paper No. 7, filed February 1, 1999 has overcome the objection to the specification in the previous office action, and the rejection is withdrawn.
2. Applicant's amendments to the specification in Paper No. 7, filed February 1, 1999 has overcome the rejection of claims 1, 3, 10, 15 and 16 under 35 USC 112, second paragraph in the previous office action, and the rejection is withdrawn.
3. Applicant's arguments filed February 1, 1999 regarding the rejection of claims 1-20 under 35 USC 103(a) have been fully considered but they are not persuasive. The response to the arguments is contained in the rejection repeated below.

### ***Claim Rejections - 35 USC § 103***

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

5. Claims 1-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Itoh et al. (A3), Kausch et al. (B1), Kawaguchi et al. (B2) and Hoffman et al. (B3).

Art Unit: 1636

The claims are drawn to a process for the isolation of nucleic material in an aqueous phase by adsorption of the nucleic material on a solid acrylamide polymer which is made from a first monomer and a second monomer which is a copolymer which has been functionalized to adsorb the nucleic material at either a pH of 7 or less, an ionic strength buffer of less than  $10^{-2}$  M, or a temperature less than the LCST of the polymer. After the adsorption step there is step to desorb the nucleic material by increasing the ionic strength of the buffer to greater than  $10^{-2}$ , where the pH may be increased to greater than 7, or the temperature may be increased to be greater than the LCST of the polymer. The discontinuous phase (the solid acrylamide polymer) may be separated from the aqueous phase, and the separation may be done by filtration, centrifugation, sedimentation, precipitation or the application of a magnetic field. The solid acrylamide polymer may be coated onto a non-adsorbing core which may be polystyrene, or may comprise a magnetic compound. The copolymer may comprise a nucleic acid fragment which may be a primer or probe, which may hybridize, under suitable conditions, to the nucleic material. Various acrylamide monomers for making the polyacryalmide are claimed, and as well, various cross-linking agents are claimed.

Itoh et al. taught (see especially pages 16, 18, 21, 24, 27, 44-45, 47-50 and claim 13) a process for the isolation of nucleic material in an aqueous phase by adsorption of the nucleic material on a solid acrylamide polymer which is made from a first monomer and a second monomer which is a copolymer which has been functionalized to adsorb the nucleic material at either a pH of 7 or less, or a temperature less than the LCST of the polymer. After the adsorption

Art Unit: 1636

step there is step to desorb the nucleic material by increasing the pH, or the temperature may be increased to be greater than the LCST of the polymer. The copolymer may comprise a nucleic acid fragment which may be a primer or probe, which may hybridize, under suitable conditions, to the nucleic material. Various acrylamide monomers for making the polyacrylamide are claimed, and as well, various cross-linking agents are claimed. Itoh et al. taught the use of the method with the copolymer being an affinity ligand.

While Itoh et al. did not specifically teach the use of a low ionic strength binding buffer nor the increased ionic strength of an eluting buffer, one of ordinary skill in the art would know that the use of an affinity matrix would require the use of elements such as a low ionic strength binding buffer and an increased ionic strength buffer to elute the bound nucleic material.

Itoh et al. did not teach the discontinuous phase (the solid acrylamide polymer) may be separated from the aqueous phase, and the separation may be done by filtration, centrifugation, sedimentation, precipitation or the application of a magnetic field, nor where the solid acrylamide polymer may be coated onto a non-adsorbing core which may be polystyrene, or may comprise a magnetic compound.

a) Applicants have argued that Itoh et al. taught at pages 44-45, the "release of valuable substances" from the polymer at low temperatures and retention of the "valuable substances" at high temperatures which is contrasted to the instant claimed invention which releases "valuable substances" at high temperatures and retains "valuable substances" at low temperatures.

Art Unit: 1636

A further reading of Itoh et al. at page 47, lines 6-24 reveals a teaching of the general mechanism of action of the polymer. Stating that high molecular weight substances are retained at low temperatures and released at high temperatures. While Itoh et al. did not contemplate nucleic acids to be treated in this manner, it is clear that an understanding of the general mechanism of action of the polymer is sufficient to teach one of skill in the art how to use the polymer.

The general mechanism of action of the polymer being: At temperatures below the critical solution temperature of the polymer (LCST), the pores of the polymer are open and "valuable substances" may be trapped in the interior of the pores of the polymer, and at a temperatures above the critical solution temperature of the polymer (UCST), the pores of the polymer shrink, expelling small molecular weight "valuable substances" within the pores as the polymer shrinks, and entrapping "valuable substances" which are too large to escape the pores as they shrink, or where the "valuable substances" are bound to the interstices of the pores. Hence, the general teachings of Itoh et al. are sufficient to teach one of skill in the art how to use the polymer to either entrap or expel a "valuable substance" in the pores of the polymer as the temperature of the solution rises above the critical solution temperature of the polymer.

Hoffman et al. taught (see especially the Summary of the invention and column 9, line 15 bridging to column 10, line 51) the use of an acrylamide polymer such as NIPAM, which was copolymerized with monomers which bound nucleic acids and proteins where the moiety of interest was adsorbed at an temperature below the LCST of the polymer and then desorbed at a

Art Unit: 1636

temperature above the LCST. Hoffman et al. also taught the adsorption of a desired moiety onto the polymer with a low ionic strength or pH buffer and the desorption of the desired moiety with a high ionic strength or pH buffer.

b) Applicants have conceded that Hoffman et al. taught the release of "valuable substances" from the polymer by increasing the temperature of the solution or by increasing the ionic strength of the solution. However, applicants have argued that Hoffman et al. and Itoh et al. are not combinable because Itoh et al. did not teach that a "valuable substance" may be released by increasing the temperature of the polymer.

Since Itoh et al. did in fact teach the release of a "valuable substance" from the polymer as the temperature of the solution rises (see above), this argument is not found convincing.

Kawaguchi et al. taught (see especially columns 3-8) an acrylamide polymer coated onto beads which were bound to DNA which were used to bind proteins at a low ionic strength and elute the proteins at a high ionic strength, where the beads did not non-specifically adsorb proteins. The beads were isolated by centrifugation or filtration.

Kausch et al. taught (see especially the abstract and columns 3-10) an acrylamide polymer coated onto beads which comprised a magnetic compound. The acrylamide polymer coated beads were used to reversibly bind DNA using probes. The binding reaction took place in low ionic strength buffer and the release was effected with high ionic strength buffer. The magnetic compound in the acrylamide coated beads allowed the isolation of the bound material by a magnetic field.

Art Unit: 1636

It would have been obvious to one of ordinary skill in the art at the time of the instant invention to combine the teachings of Itoh et al., Hoffman et al., Kawaguchi et al. and Kausch et al. to produce the instant invention because Itoh et al., Hoffman et al., Kawaguchi et al. and Kausch et al. were all using acrylamide polymers with a copolymer which would adsorb and desorb nucleic acids and proteins. Itoh et al. taught the use of the acrylamide polymer in bead form, and coated onto solid supports. Hoffman et al. taught the adsorption of nucleic acid in a low ionic strength buffer and the desorption of the nucleic acid in a high ionic strength buffer. Kawaguchi et al. and Kausch et al. taught the coating of polyacrylamide onto solid bead supports, and Kausch et al. taught the polyacrylamide coated beads which comprised a magnetic compound to facilitate the isolation of the bead with the bound DNA in a magnetic field.

One of ordinary skill in the art would have been motivated at the time of the instant invention to combine the teachings of Itoh et al., Hoffman et al., Kawaguchi et al. and Kausch et al. to produce the instant invention because Itoh et al., Hoffman et al., Kawaguchi et al. and Kausch et al. taught the desirable use of acrylamide polymers with a copolymer which would adsorb and desorb nucleic acids and proteins. Itoh et al. taught the use of the acrylamide polymer in bead form, and coated onto solid supports. Hoffman et al. taught the desirable method of adsorption onto an acrylamide solid support of nucleic acid in a low ionic strength buffer and the desorption of the nucleic acid in a high ionic strength buffer. Kawaguchi et al. and Kausch et al. taught the coating of polyacrylamide onto solid bead supports, and Kausch et al. taught the polyacrylamide coated beads which comprised a magnetic compound to facilitate the isolation of

Art Unit: 1636

the bead with the bound DNA in a magnetic field. Further, a person of ordinary skill in the art would have had a reasonable expectation of success in producing the instant claimed invention given the teachings of Itoh et al., Hoffman et al., Kawaguchi et al. and Kausch et al.

***Conclusion***

6. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

7. Certain papers related to this application are *welcomed* to be submitted to Art Unit 1636 by facsimile transmission. The FAX numbers are (703) 308-4242 and 305-3014. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 CFR 1.6(d)). NOTE: If applicant *does* submit a paper by FAX, the original copy should be retained by the applicant or

Art Unit: 1636

applicant's representative, and the FAX receipt from your FAX machine is proof of delivery. NO DUPLICATE COPIES SHOULD BE SUBMITTED, so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning this communication or earlier communications should be directed to Dr. William Sandals whose telephone number is (703) 305-1982. The examiner normally can be reached Monday through Friday from 8:30 AM to 5:00 PM, EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. George Elliott can be reached at (703) 308-4003.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group Receptionist, whose telephone number is (703) 308-0196.

William Sandals, Ph.D.

Examiner

April 5, 1999



NANCY DEGEN  
PRIMARY EXAMINER